Sermorelin Peptide Therapy: A Clinician's Guide

What Is Sermorelin?

The molecule

Sermorelin acetate is a synthetic analog of the first 29 amino acids of human growth hormone releasing hormone (GHRH 1-29 (PMID 18031173)). Native GHRH is a 44-amino-acid peptide, and sermorelin reproduces its first 29 amino acids, a fragment that is sufficient to stimulate growth hormone secretion from the anterior pituitary (PMID 18031173). Sermorelin was previously marketed under the brand name Geref for diagnosing and treating growth hormone deficiency in children, and the branded product was later discontinued (PMID 18031173).

Mechanism of action

Sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering the release of stored growth hormone in a pulsatile pattern that mirrors the body's natural secretion rhythm (PMID 1379256). Because GHRH acts through the pituitary, GH release remains pulsatile and subject to the body's normal feedback regulation, and IGF-1 rises in response to the body's own GH rather than to a sustained exogenous dose (PMID 1379256). In practical terms, a patient's own regulatory circuitry continues to govern how much hormone is actually released.

Sermorelin vs. recombinant HGH

This is the most common question patients and clinicians raise, and the distinction is clinically important. Recombinant human growth hormone (rHGH) delivers GH directly, bypassing the pituitary, the hypothalamus, and the physiological feedback loop that governs when and how much GH the body produces. In randomized trials in healthy older adults, recombinant HGH produced small changes in body composition but increased rates of soft-tissue edema, joint pain, carpal tunnel syndrome, and gynecomastia, and somewhat higher rates of diabetes and impaired fasting glucose (PMID 17227934)).

Sermorelin works upstream. Because sermorelin acts on the pituitary, it requires a functioning pituitary gland to work, which limits both its effect and its potential for excess (PMID 18031173). Patients with pituitary dysfunction will not respond to sermorelin. Patients with intact but age-diminished pituitary function often do.

Clinical Applications

Age-related GH decline (somatopause)

Somatopause refers to the progressive decline in GH secretion that begins in early adulthood and continues with age (PMID 3972964). In healthy men, daily GH production falls by an average of about 14% per decade of age (PMID 1939523). GHRH analogs such as sermorelin have been studied in older adults, where they raised GH and IGF-1 levels while preserving physiological GH release (PMID 1379256).

Sleep

Growth hormone secretion is tightly coupled to slow-wave sleep (PMID 10984255). Evidence that sermorelin improves sleep is limited: in a 16-week trial of a nightly GHRH analog in adults aged 55 to 71, self-reported sleep quality did not change (PMID 9141536).

Body composition

In a 16-week trial in adults aged 55 to 71, a nightly sermorelin-like GHRH analog increased lean body mass in men but not women, with no other changes in body composition (PMID 9141536). The effect is not pharmacologic weight loss; patients who expect rapid or dramatic changes are usually disappointed and often misdirected by marketing that overstates what sermorelin can do.

Recovery and post-injury

Clinicians working with active adults sometimes incorporate sermorelin into recovery protocols, alone or in combination with GHRP peptides. There is little published evidence on sermorelin for post-injury recovery, and such use is largely based on clinical observation and the general rationale of supporting the GH axis during rehabilitation.

Pediatric use cases (historical)

Sermorelin was historically used for diagnostic evaluation of GH deficiency in pediatric patients and, in some cases, as adjunctive therapy for idiopathic short stature. Those uses have largely moved to other diagnostics and therapeutics, and pediatric sermorelin is not a typical contemporary use case.

Sermorelin Dosing and Administration

The ranges below describe commonly used protocols and are not a prescription. Dosing should be individualized by a licensed provider based on indication, baseline labs, body weight, and response.

Subcutaneous injection protocols

• Doses used in clinical studies have varied; in one trial in older adults, a GHRH analog was self-injected subcutaneously at 10 mcg/kg each night (PMID 9141536).
• Injection sites: abdominal subcutaneous tissue, rotated to avoid lipohypertrophy.
• Reconstitution and storage: compounded sermorelin is typically reconstituted with bacteriostatic water and refrigerated after mixing.

Why dosing is timed before sleep

Endogenous GH release peaks during early slow-wave sleep (PMID 10984255). Sermorelin is usually given once daily at bedtime, as in clinical studies, to coincide with the body's natural nocturnal GH release (PMID 18031173). Dosing shortly after meals, especially high-glycemic meals, is generally avoided because elevated blood glucose suppresses GH secretion (PMID 41524818).

Cycle duration and monitoring

Treatment courses are typically monitored with laboratory tests at baseline, during therapy, and at the end of the course. IGF-1 is the main laboratory marker used to gauge the effect of therapies that raise GH, since its levels rise in response to increased GH secretion (PMID 1379256). Fasting glucose, HbA1c, and thyroid function are also tracked because increased GH signaling can affect glucose metabolism and can unmask underlying low thyroid function (PMID 17201804).

Combination protocols

Sermorelin is sometimes paired with a growth hormone releasing peptide (GHRP-2, GHRP-6, ipamorelin), because GHRH and GHRPs given together act synergistically to produce a much larger GH pulse (PMID 19240251). The combination can amplify GH release in patients who respond poorly to sermorelin alone. A longer-acting GHRH analog, CJC-1295 (with or without DAC), is sometimes substituted for sermorelin in protocols prioritizing fewer injections (PMID 16352683). Each combination has distinct safety and dosing considerations best worked through with a clinician experienced in the space.

Benefits Supported by Evidence

What the literature shows

Sermorelin's core claim, that it stimulates endogenous GH release via the GHRH receptor, is well-established pharmacology (PMID 18031173). Studies in adults with age-related GH decline have shown measurable increases in IGF-1, sleep-phase GH pulses, and in some trials, changes in body composition and subjective well-being over 3–6 month periods (PMID 9141536).

What's anecdotal vs. peer-reviewed

Effects on sleep, recovery, and energy are less well established than effects on GH and IGF-1; in one 16-week trial of a GHRH analog in older adults, sleep quality did not change, although men reported improved general well-being (PMID 9141536). That doesn't mean those benefits aren't real, it means the evidence for them is lower-grade, and clinicians should frame them accordingly.

Realistic timelines

• In one trial of a GHRH analog in older adults, IGF-1 rose within 2 weeks and stayed elevated for about 12 weeks before drifting back toward baseline by week 16 (PMID 9141536).
• By about 4 months, trial results on body composition have been modest, such as a small gain in lean body mass in men only, so this is a reasonable point to decide whether to continue, taper, or stop (PMID 9141536).

Safety Profile and Side Effects

Common side effects

• Injection site reactions, redness, mild swelling, itching
• Transient headache, particularly in the first 1–2 weeks
• Flushing or warmth after dosing
• Mild dizziness in a minority of patients

Less common

• Hypersensitivity reactions
• Altered glucose metabolism (warrants HbA1c monitoring)
• Fluid retention or mild peripheral edema at higher doses
• Joint aches or transient arthralgia

Contraindications

• Active malignancy or recent history of cancer
• Pregnancy and breastfeeding
• Severe untreated diabetes or uncontrolled hyperglycemia
• Known hypersensitivity to sermorelin or related peptides
• Pituitary tumors or severe pituitary dysfunction

Drug interactions

Glucocorticoids, thyroid hormone replacement outside target ranges, and medications affecting insulin sensitivity can alter GH-axis response and should be accounted for in dosing. A complete medication and supplement review at intake is standard.

Regulatory Status in the United States

FDA framework for sermorelin in 2026

The branded sermorelin products (Geref, Geref Diagnostic) were discontinued by the manufacturer and are no longer marketed in the United States. In the United States, sermorelin is generally obtained through compounding pharmacies filling patient-specific prescriptions from licensed clinicians, and its compounding status is set by FDA and can change. For current compound-specific FDA positioning, see the regulatory tracker.

Prescription requirement

In the United States, sermorelin requires a prescription from a licensed clinician. Obtaining it without a prescription, or from research-chemical suppliers, bypasses legal safeguards and gives no assurance of what the product contains.

Compounding pharmacy vs. research-chem

The same sourcing caveats apply to sermorelin as to any peptide: 503A and 503B pharmacies are the compliant, quality-controlled channels. Products labeled for research use only are not intended for human use, and testing of unregulated performance-enhancing products, including peptide hormones, has found that most did not contain the labeled substance in the stated amount (PMID 28156209). The Peptide Association supplier network verifies pharmacy sourcing for every protocol our clinician network approves.

Patient Selection

Who's a candidate for sermorelin therapy?

The strongest candidate is an adult with laboratory-confirmed age-related decline in IGF-1 or documented clinical features of diminished GH signaling (persistent sleep dysfunction, slowed recovery, unfavorable body composition shifts despite lifestyle intervention) who has ruled out alternative explanations, has normal thyroid and adrenal function, and understands that sermorelin is evidence-informed rather than indicated therapy.

Pre-therapy workup

• IGF-1 (primary baseline)
• Complete metabolic panel and CBC
• Fasting glucose and HbA1c
• Lipid panel
• Full thyroid panel (TSH, free T3, free T4)
• Testosterone (total and free) or estradiol as clinically indicated
• PSA in men over 40 prior to GH-axis therapy
• Baseline body composition measurement (DEXA or equivalent)

Who shouldn't use sermorelin

In addition to the formal contraindications listed above, patients with unexplained elevated IGF-1, uncontrolled metabolic disease, or expectations of pharmacologic weight loss are poor candidates and should pursue different strategies.

Cost Expectations

Typical monthly cost range

Compounded sermorelin therapy in the U.S. typically ranges from $200–$500 per month depending on dose, the compounding pharmacy, and whether sermorelin is dispensed stand-alone or as part of a combined protocol with a GHRP or CJC-1295. Consultation, labs, and follow-up are billed separately unless bundled in a concierge program.

Insurance coverage

Sermorelin is not typically covered by commercial insurance for age-related GH decline, which is the most common indication. Assume cash-pay.

Long-term cost planning

Because sermorelin is often used in multi-month cycles rather than as chronic daily medication, annual cost can be lower than the monthly rate suggests. Patients and providers should plan cycles and re-evaluations in advance so there are no surprises on the billing side or the protocol side.

How to Find a Sermorelin Provider

What to look for

• Active state medical license and board certification in a relevant specialty.
• Transparent sourcing, the provider should name their compounding pharmacy and explain sourcing standards.
• Labs-first approach, comprehensive baseline workup and scheduled follow-up labs.
• Experience with the GH axis specifically - sermorelin, GHRPs, CJC-1295, and appropriate combinations.

Getting Started With Sermorelin Therapy

The guided intake asks about your goals, health history, and lab needs. The AI-proposed protocol that comes out of it is then reviewed with you by a licensed clinician in our network at a consultation, who weighs your GH-axis labs and history and decides what is clinically appropriate. Telehealth is available in many states, which can help patients in regions with few in-person options.